Repligen Corp (RGEN) Com Stk USD0.01

Sell:$131.01Buy:$131.04Price increased$8.76 (7.15%)

NASDAQ:Price increased1.96%
Market closed |
Prices delayed by at least 15 minutes
Sell:$131.01
Buy:$131.04
Change:Price increased$8.76 (7.15%)
Deal now
Market closed |
Prices delayed by at least 15 minutes
Sell:$131.01
Buy:$131.04
Change:Price increased$8.76 (7.15%)
Market closed |
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its franchises include filtration, chromatography, process analytics and proteins. Its filtration franchise includes product offering covering upstream and downstream technologies. Its filtration products include XCell Alternating Tangential Flow (ATF) Cell Retention Systems, Flat Sheet Cassettes, Hollow Fiber Consumables, Tangential Flow Filtration Systems and Fluid Management. Its chromatography franchise includes products used in downstream purification, development, manufacturing and quality control of biological drugs. Its chromatography franchise includes OPUS Pre-Packed Columns, KRM Chromatography Systems and other additional chromatography products. Its process analytics include Downstream process analytical technology (PAT) and Upstream PAT. Its Proteins include Protein A Affinity Ligands, AVIPure Resins for New Modalities and Growth Factors.

Key people

Martin D. Madaus
Independent Chairman of the Board
Olivier Loeillot
President, Chief Executive Officer, Director
Jason K. Garland
Chief Financial Officer
James R. Bylund
Chief Operating Officer
Ralf Kuriyel
Senior Vice President - Research and Development
Karen A. Dawes
Lead Independent Director
Nicolas M. Barthelemy
Independent Director
Konstantin Konstantinov
Independent Director
Carrie Eglinton Manner
Independent Director
Click to see more

Key facts

  • Shares in issue
    56.40m
  • EPIC
    RGEN
  • ISIN
    US7599161095
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • Market cap
    $6.91bn
  • Employees
    2,000
  • Exchange
    NASDAQ
  • Index
    S&P 400 Mid Cap, TR Equity United States Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.